Registration Frequencies
Weekly updated frequencies of observation starts at registration by medication are shown.Fig 1) Patient numbers by biologic treatment at inclusion
Last update: | total n=
![Fig 1) Patient numbers by biologic treatment at inclusion](https://www.psobest.de/wp-content/uploads/2018/07/Fig1.png)
Fig 2) PsoBest registry: patient numbers by non-biologic treatment at inclusion
Last update: | total n=
Show table for Fig. 1/2Hide table
Inclusion Treatment | Patient Number | of that with similar agents (e.g. Biosimilars) |
---|---|---|
Adalimumab | 1069 | 1315 |
Bimekizumab | 324 | 0 |
Brodalumab | 570 | 0 |
Certolizumab | 222 | 0 |
Efalizumab | 35 | 0 |
Etanercept | 312 | 71 |
Golimumab | 25 | 0 |
Guselkumab | 1690 | 0 |
Infliximab | 103 | 1 |
Ixekizumab | 960 | 0 |
Risankizumab | 1568 | 0 |
Secukinumab | 2028 | 0 |
Tildrakizumab | 1433 | 0 |
Ustekinumab | 777 | 0 |
Apremilast | 743 | 0 |
Ciclosporin | 402 | 0 |
Fumaderm® | 2693 | 0 |
Skilarence® | 3211 | 0 |
Methotrexat | 3920 | 0 |
Tofacitinib | 2 | 0 |
Upadacitinib | 5 | 0 |
Deucravacitinib | 121 | 0 |
other systemics | 356 | 0 |
Fig. 3) Rate of patients by medication class at inclusion
Last update: | total n=
Fig. 4) Rate of patients by type of registry site
Last update: | total n=
Fig. 5) Registered PsoBest centers
Last update: | n= | updated monthly